Epigenetic Modulators and Immunotherapy in Malignant MelanomaOA
Despite the use of targeted and/or immune-based therapeutic approaches,mortality rates among melanoma patients are high,mainly due to drug-induced resistance mechanisms.In parallel,alterations of epigenetic mechanisms(e.g.,deregulated patterns of DNA methylation,aberrant histone modifications and abnormal expression levels of non-coding RNAs[ncRNAs])have been associated not only with the pathophysiology of melanoma but also with the resistance against various immunotherapeutic drugs.In this review article,we discuss the involvement of different types of epigenetic mechanisms in melanoma progression.In addition,we report on melanoma’s immune environment and immunosuppressive mechanisms while we highlight the role of immune checkpoint inhibitors(ICIs)as an anti-melanoma therapeutic approach.Moreover,we describe the underlying mechanism(s)by which deregulated epigenetic patterns promote drug resistance against ICIs and how epigenetic drugs(utilized either alone or in combination with various ICIs)can reverse immune resistance.Furthermore,we discuss the major limitations and future directions towards clinical translation of epigenetic drugs,mainly in combination with ICIs.Finally,we state the potential use of emerging technologies(e.g.,single-cell transcriptomics and spatial transcriptomics),along with epigenetic priming for improvement of clinical implementation and therapeutic outcomes in melanoma management.
Ioannis Anestopoulos;Sotiris Kyriakou;Maria Deligiorgi;Dimitrios T.Trafalis;Sotiris Botaitis;Rodrigo Franco;Aglaia Pappa;Mihalis I.Panayiotidis
Department of Cancer Genetics,Therapeutics&Ultrastructural Pathology,the Cyprus Institute of Neurology&Genetics,Nicosia,CyprusDepartment of Cancer Genetics,Therapeutics&Ultrastructural Pathology,the Cyprus Institute of Neurology&Genetics,Nicosia,CyprusLaboratory of Pharmacology,Medical School,National&Kapodistrian University of Athens,Athens,GreeceLaboratory of Pharmacology,Medical School,National&Kapodistrian University of Athens,Athens,GreeceDepartment of Surgery,School of Medicine,University Hospital,Democritus University of Thrace,Alexandroupolis,GreeceSchool of Veterinary Medicine&Biomedical Sciences,University of Nebraska-Lincoln,Lincoln,NE,USA Redox Biology Centre,University of Nebraska-Lincoln,Lincoln,NE,USADepartment of Molecular Biology&Genetics,Democritus University of Thrace,Alexandroupolis,GreeceDepartment of Comparative Biomedical Sciences,College of Veterinary Medicine,Mississippi State University,Starkville,MS,USA
医药卫生
Malignant melanomaepigeneticsDNA methyltransferase inhibitorsHistone Deacetylase inhibitorsimmunotherapyimmune checkpoint inhibitors
《Oncology Research》 2026 (8)
P.1-35,35
supported by a grant provided by the Cyprus Institute of Neurology and Genetics,Nicosia,Cyprus under Telethon Cyprus(Mihalis I.Panayiotidis)Hellenic Foundation for Research and Innovation(H.F.R.I.)under the“First call for H.F.R.I.research projects to support faculty members and researchers and the procurement of high-cost research equipmentProject Number:HFRI-FM17C3-2007”(Aglaia Pappa and Mihalis I.Panayiotidis)《PENSCREEN-GR:An Open-Access Research Infrastructure of Target-Based Screening Technologies and Chemical Biology for Human and Animal Health,Agriculture and Environment》(MIS 5002691)which is implemented under the Action“Reinforcement of the Research and Innovation Infrastructure”funded by the Operational Programme“Competitiveness,Entrepreneurship and Innovation”(NSRF 2014-2020)co-financed by Greece and the European Union(European Regional Development Fund)(Aglaia Pappa).
评论